ReviewCancer reports (Hoboken, N.J.)2025
Emerging Trends in Neoadjuvant Immunotherapy for Hepatocellular Carcinoma: A Focus on Liver Transplant Candidates.
Review in Cancer reports (Hoboken, N.J.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Cyclosporine in hematological disorders: mechanisms, clinical practice and emerging advances.Annals of hematology · 2026Review
- Evolving patterns of hepato-pancreato-biliary surgery in the immunotherapy era.Frontiers in immunology · 2026Article
- Protein Induced by Vitamin K Absence or Antagonist II in Primary Liver Cancer: Basic Research Insights and Clinical Applications.Journal of clinical and translational hepatology · 2025Review
- Emerging Trends in Neoadjuvant Immunotherapy for Hepatocellular Carcinoma: A Focus on Liver Transplant Candidates.Cancer reports (Hoboken, N.J.) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundImmunotherapy has emerged as a promising neoadjuvant strategy for hepatocellular carcinoma (HCC), with growing evidence supporting its role in tumor downstaging and enabling radical resection. Liver transplantation remains a curative option for HCC, and the integration of neoadjuvant immunotherapy prior to transplantation holds potential to improve staging outcomes and reduce postoperative recurrence. However, this approach necessitates careful evaluation of transplant-related immunological risks, particularly the risk of allograft rejection. RECENT
findingsRecent clinical trials have provided key data on the efficacy and safety of pre-transplant immunotherapy. These studies highlight the importance of patient selection and risk management strategies to optimize treatment outcomes. Novel immunotherapeutic approaches are being explored, with a focus on identifying patients most likely to benefit from neoadjuvant therapy prior to liver transplantation.
conclusionThis review synthesizes emerging trends in the use of neoadjuvant immunotherapy for HCC patients undergoing liver transplantation. While immunotherapy shows promise in enhancing staging success and reducing recurrence, careful consideration of immunological risks and patient-specific factors is essential. Future research should continue to evaluate the long-term benefits and safety of this approach, as well as refine strategies for patient selection and risk mitigation. The integration of immunotherapy into pre-transplant care may represent a transformative advancement in the treatment of HCC, provided these challenges are addressed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.